1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Participating sites in the Minnie Pearl Cancer Research Network include: Tennessee Oncology PLLC, Nashville, TN; South Carolina CCOP, Spartanburg, SC; Hematology Oncology of South Florida, Miami, FL; Montgomery Cancer Center, Montgomery, AL; Oncology Associates of Western Kentucky, Paducah, KY; Louisiana Oncology Associates, Lafayette, LA; Grand Rapids CCOP, Grand Rapids, MI; Terrebonne General Cancer Center, Houma, LA; and Lewis-Gale Oncology Clinic, Salem, VA.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
A Minnie Pearl Cancer Research Network Phase II Trial†
Article first published online: 13 NOV 2000
DOI: 10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F
Copyright © 2000 American Cancer Society
Additional Information
How to Cite
Hainsworth, J. D., Burris, H. A., Litchy, S., Morrissey, L. H., Barton, J. H., Bradof, J. E. and Greco, F. A. (2000), Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. Cancer, 89: 328–333. doi: 10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F
- †
Publication History
- Issue published online: 13 NOV 2000
- Article first published online: 13 NOV 2000
- Manuscript Revised: 6 MAR 2000
- Manuscript Accepted: 6 MAR 2000
- Manuscript Received: 15 OCT 1999
Funded by
- Rhone-Poulenc Rorer
- The Minnie Pearl Foundation
- Abstract
- Article
- References
- Cited By
Keywords:
- weekly docetaxel;
- elderly patients;
- nonsmall cell lung carcinoma;
- single agent chemotherapy
Thirty-nine elderly or poor performance status patients with advanced, previously untreated nonsmall cell lung carcinoma received weekly treatment with docetaxel. Treatment was well tolerated, resulted in minimal myelosuppression, and produced a response rate of 18% with a 1-year survival rate of 27%.
Abstract
BACKGROUND
Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatment of elderly patients with newly diagnosed advanced nonsmall cell lung carcinoma.
METHODS
Thirty-nine patients with advanced, previously untreated nonsmall cell lung carcinoma entered this Phase II trial between February 1998 and January 1999. Patients were required either to be age ≥ 65 years or to be poor candidates for combination chemotherapy due to coexistent medical illnesses. All patients received docetaxel, 36 mg/m2, administered weekly for 6 consecutive weeks, followed by 2 weeks without treatment. Patients were reevaluated after 8 weeks of treatment; responding patients continued weekly docetaxel for a maximum of 32 weeks or until disease progression.
RESULTS
Weekly docetaxel was well tolerated by this elderly group of patients with nonsmall cell lung carcinoma. Grade 3 leukopenia was noted in only 3 patients (8%), and no patient developed Grade 4 myelosuppression. Grade 3/4 nonhematologic toxicity also was uncommon; fatigue/asthenia was reported in 4 patients (10%). Seven of 38 evaluable patients (18%) had objective responses to weekly docetaxel whereas an additional 13 patients (34%) had a minor response or stable disease at first reevaluation. The median survival in this group of elderly patients was 5 months, with a 1-year actuarial survival rate of 27%.
CONCLUSIONS
The results of the current study show that weekly docetaxel is active and well tolerated in elderly patients with advanced nonsmall cell lung carcinoma and provides an additional treatment option for these patients, who often tolerate combination chemotherapy regimens poorly. Cancer 2000;89:328–33. © 2000 American Cancer Society.